141 results about "Endometrial Carcinomas" patented technology

The disclosure relates to methods, compositions, and combinations for the treatment of endometrial cancer. Specifically, the disclosure relates to methods of treating endometrial cancer in a subject in need thereof, comprising administering to the subject one or more chemotherapy agents, an anti-PD-L1 antibody or an antigen-binding fragment thereof, and optionally a PARP inhibitor. The disclosure also relates to combinations for use in the treatment of endometrial cancer comprising one or more chemotherapy agents, an anti-PD-L1 antibody or an antigen-binding fragment thereof, and optionally a PARP inhibitor.

Endometrial cancer (EC) is the most common gynecologic cancer in developed countries and the fourth most common cancer affecting women in the US. In contrast to other cancers, rates of EC continue to rise, and there are indications that social determinants of health and race and / or ethnicity contribute to risk. Thus, the methods described herein provide a non-invasive means of measuring biomarkers in the local cervicovaginal microenvironment. These novel biomarkers may be used for diagnosing and / or predicting women who are "at risk" for the development and progression of endometrial cancer (EC; e.g., EC type 1). Specifically, the methods herein may include obtaining a cervicovaginal lavage (CVL) or vaginal swab sample from a patient and producing a profile of at least five or more biomarkers from the collected sample.

The invention relates to the technical field of biological detection, in particular to a nucleic acid sequence combination for detecting cervical cell gene methylation, a kit and application. The nucleic acid sequence combination for detecting the methylation of the cervical cell gene, provided by the invention, can specifically detect the methylation of ABCC9 and LINC00605 genes of an endometrial cancer cervical exfoliated cell sample, which are different from those of a healthy human cervical exfoliated cell sample, and the kit for detecting the methylation of the cervical cell gene, which is prepared by utilizing the nucleic acid sequence combination, can be used for detecting the methylation of the cervical cell gene. The kit is applied to diagnosis / screening of endometrial cancer, has relatively high detection sensitivity and specificity on stage I and stage II endometrial cancer, is simple to operate and beneficial to popularization and application, and noninvasive material drawing is realized.

The invention discloses an early noninvasive endometrial cancer assessment method based on machine learning, and the method comprises the following steps: S1, obtaining the index data of a potential endometrial lesion patient in advance, and carrying out the data integration based on the index data according to a preset standard to obtain a feature set; s2, performing standardized preprocessing on the feature set in the step S1 to obtain a training set and a test set of standardized endometrial lesion data; s3, constructing a disease prediction model based on a preset multi-modal machine learning model and used for predicting an endometrial cancer result on the basis of the training set and the test set containing the endometrial lesion data obtained in the step S2; and S4, inputting endometrial lesion index data of a patient to be evaluated into the disease prediction model to implement early noninvasive endometrial cancer prediction evaluation so as to obtain an endometrial cancer prediction result of the patient. The method has the advantages that non-invasive screening can be met at the same time, the prediction accuracy is high, and the economic burden is small.

Endometrial cancer (EC) is the most common gynecologic cancer in developed countries and the fourth most common cancer affecting women in the US. In contrast to other cancers, rates of EC continue to rise, and there are indications that social determinants of health and race and / or ethnicity contribute to risk. Thus, the methods described herein provide a non-invasive means of measuring protein biomarkers in the local cervicovaginal microenvironment. These novel biomarkers may be used for diagnosing and / or predicting women that are “at risk” for the development and progression of endometrial cancer (EC; e.g., EC type 1). Specifically, the methods herein may include obtaining a sample (e.g., CVL, vaginal swabs, or secretions) from a patient and producing a profile of at least five or more protein biomarkers from the collected sample.

The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer and application thereof, and belongs to the field of markers for detecting ovarian cancer. The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer. The specific metabolic marker combination comprises phosphatidylcholine 36: 6, sphingomyelin d40: 2 and sphingomyelin d41: 2. According to the invention, a metabonomics technology is used to screen out a specific metabolism marker combination for diagnosing ovarian cancer, and the specific metabolism marker combination has high sensitivity in ovarian cancer diagnosis and has high diagnosis capability for ovarian cancer diagnosis. The specific metabolic marker combination also has high specificity in ovarian cancer diagnosis, but is not applicable to diagnosis of endometrial cancer and cervical cancer. In addition, the plasma sample acquisition mode has the advantages of non-invasiveness and convenience, and has a wide application prospect in the research of biomarkers.

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer associated with FBOX21 mediated p85a ubiquitination such as, for example, cancer (e.g., sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer such as, for example, a primary or secondary tumor within a subject's brain, breast, kidney, pancreas, lung, colon, prostate, lymphatic system, liver, ovary, or cervix. Additional examples of cancers for which the disclosed compounds and compositions can be useful include, but are not limited to, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanomas, gliomas, leukemia, lymphoma, chronic myeloproliferative disorders, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinomas, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

This document relates to methods and materials for assessing and / or treating mammals (e.g., humans) having endometrial cancer. For example, methods and materials for identifying endometrial cancers likely to respond to a particular cancer treatment (e.g., a platinum based cancer therapy) are provided. This document also relates to materials and methods for using one or more cancer treatments to treat a mammal (e.g., a human) identified as likely to respond to a particular cancer treatment.

The present invention provides an application of MAPK4 as a target in the preparation of a drug for treating endometrial cancer and a targeted inhibitor for treating endometrial cancer. Among them, the present invention finds that MAPK4 can be used as a target to prepare a drug for treating endometrial cancer. Based on the above application of the present invention, the problem of the lack of effective drugs for targeted treatment of endometrial cancer in the prior art can be solved, and the present invention is applicable to the field of medicine and health.

Provided is a use of an anti-PD-1 antibody combined with a chemotherapeutic agent in the treatment of tumors such as cervical cancer or endometrial cancer. In some embodiments, the chemotherapeutic agent comprises a taxane drug and / or a platinum drug. In some embodiments, the use further comprises a use of the anti-PD-1 antibody combined with bevacizumab.

The invention provides an endometrial cancer prediction method, device and equipment based on pathological deep learning, and a storage medium, and the method comprises the steps: obtaining the image data of endometrium, carrying out the spatial feature extraction of the image data of endometrium through employing a convolutional neural network, carrying out the analysis of the lesion form, tissue density and abnormal region of the spatial features, and obtaining the prediction result of the endometrial cancer. Generating an image vector; the method comprises the following steps: acquiring a historical clinical diagnosis text, and extracting a text vector associated with endometrial cancer by using a Transform model; obtaining candidate genes associated with endometrial cancer in the gene data, analyzing the candidate genes by using PCA (Principal Component Analysis) to extract mutation site information and variation types, and generating gene vectors according to the mutation site information and the variation types; and fusing the image vector, the text vector and the gene vector to generate a fusion feature, predicting the fusion feature by using a pre-trained multi-layer perceptron, and outputting a prediction result of the endometrial cancer. Early prediction of endometrial cancer is realized, and invasive surgical operations are reduced.

The present invention relates to a primer-probe combination for early detection of endometrial cancer, a methylation detection kit, and the use thereof. Provided in the present invention is a methylation gene marker for endometrial cancer detection, which specifically comprises at least one of VSX1, SYT1, ZNF132 and VWC2 genes. Measuring the methylation levels of the genes can remarkably distinguish subjects with endometrial cancer from subjects without cancer. The gene marker of the present invention can well identify subjects with endometrial cancer and subjects without cancer from each of tissue / urine / brush smear / swab / blood / lavage fluid specimens, and can achieve a good detection effect simply by means of a single index and further improve the detection efficiency by means of multi-index combination.

The present disclosure provides novel compounds, compositions, and methods for modulating one or more septin proteins, e.g., septin-2. Such compounds and compositions are useful for the treatment of a cancer, e.g., endometrial, pancreatic, lung, breast or ovarian cancer, such as serous and ovarian clear cell carcinoma.

The invention discloses a multiplex PCR (Polymerase Chain Reaction) detection kit based on microsatellite instability sites of endometrial cancer. The kit comprises a primer group and a premixed solution, the primer group comprises a primer for detecting at least one of a site BAT-25, a site BAT-26, a site NR-24, a site MONO-27, a site CAT-25, a site BAT-59 and a site BAT-60, and the primer contains two inosine (I) and a stem-loop structure (SEQ ID NO.22) so as to simultaneously detect different states of MSI Del and Ins; according to the kit, when MSI detection is used for carrying out microsatellite instability judgment on endometrial cancer on seven combination sites and corresponding target coverage sections, capillary electrophoresis detection and common PCR (Polymerase Chain Reaction) and digital PCR detection can be carried out at the same time, so that the gradient among detection result numerical values is more refined, and the MSI state is accurately defined as high, low or stable; the kit has the advantages that reagent material cost is saved, detection period is shortened, detection in an extreme period is achieved, clinical multi-sample detection requirements are met, and the kit has the advantages of high sensitivity, specificity and repeatability.

The invention provides a construction method and application of an endometrial cancer CT image segmentation model. The construction method comprises the following steps: acquiring a plurality of endometrial CT images marked with canceration regions as a training data set; constructing an endometrial cancer CT image segmentation framework, wherein the endometrial cancer CT image segmentation framework is of a U-Net structure comprising a coding unit, a bottleneck layer and a decoding unit; and training the endometrial cancer CT image segmentation architecture by using the training data set to obtain an endometrial cancer CT image segmentation model. According to the scheme, multi-scale structure change information is explicitly captured by constructing a multi-direction coding structure response operator and generating a coding structure gradient field, and representation of thin and weak boundaries and small lesions is enhanced to improve the segmentation accuracy of the model.

Antibody drug conjugate (ADC) comprising a drug moiety conjugated to antibody or antigen binding fragments thereof that bind to TROP2 disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The ADC of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the ADC disclosed herein can include carcinomas, such as lung cancer, breast cancer, head-and-neck cancer, esophagus cancer, stomach cancer, bladder cancer, pancreatic cancer, colorectal cancer, cervix cancer, endometrial cancer, ovarian cancer, laryngeal cancer, prostate cancer, thyroid cancer and oral cancer.

The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter ‘C’ region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.

This application belongs to the field of biomedicine technology, and in particular relates to the use of a KAT5 inhibitor in a cancer treatment drug, as well as a drug for treating endometrial cancer. The use of a KAT5 inhibitor in a cancer treatment drug includes applying a KAT5 inhibitor to a drug for treating cancer. This application applies a KAT5 inhibitor to a drug for treating cancer. The small molecule KAT5 inhibitor can achieve anti-tumor activity by inducing accumulation of cellular DNA damage. Furthermore, the KAT5 inhibitor can significantly inhibit the growth of cancer cells both in vitro and in vivo. This application, through verification experiments, has for the first time clarified the anti-tumor effect of a KAT5 inhibitor, which has important pharmaceutical development value and market benefits.

The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and / or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.

The invention provides a deep learning-based endometrial cancer detection method and system, and relates to the technical field of cancer detection, and the method comprises the steps: obtaining preliminary survey data; determining a preliminary survey result; determining whether histopathology detection is needed or not; if histopathology detection needs to be carried out, hysteroscope guided biopsy data of the patient to be detected are obtained, and a histopathology definite diagnosis result is determined; determining whether further detection is needed or not; if further detection is needed, acquiring patient physiological state data, medical image data and laboratory detection data of the to-be-detected patient; determining a physiological state influence coefficient of the patient; processing the medical image data, the laboratory detection data and the physiological state influence coefficient of the patient through a trained tumor deterioration time prediction model, and determining predicted tumor deterioration time; determining an endometrial cancer danger coefficient; and generating a detection report. According to the invention, the accuracy of the detection result of the endometrial cancer can be improved.

Disclosed herein are novel compounds that are Mpsl / TTK inhibitors. Also disclosed are compositions comprising the compounds and methods of using the compounds in treating various diseases. In some embodiments, some such compounds, compositions, and their uses may be useful for the treatment of cancer. In some implementations, the cancer is brain cancer, glioblastoma multiforme, head and neck cancers, colorectal cancer, stomach or gastric cancer, pancreatic cancer, melanoma, bladder cancer, kidney cancer, renal cell carcinoma, breast cancer, ovarian cancer, lymphoma, thyroid cancer, mesothelioma, sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer, or endometrial cancer.

The present disclosure provides methods, compositions, uses, and kits for treatment of solid cancer (e.g., urothelial cancer (UC), head and neck squamous cell carcinoma (HNSCC), cervical cancer (CC), endometrial carcinoma (EC), or triple-negative breast cancer (TNBC)) using anti-human Nectin-4 therapeutics.

Provided are a novel DNA methylation marker TAGMe-5 for tumor identification and a use thereof. The tumor marker TAGMe-5 shows a significant DNA methylation difference in para-carcinoma tissues and carcinoma tissues, the difference has remarkable statistical significance, and the difference is shown in a plurality of tumors such as solid tumors and non-solid tumors. The solid tumors comprise lung cancer, liver cancer, prostate cancer, cervical cancer, endometrial cancer, urothelial carcinoma, a biliary tract tumor, etc. The non-solid tumors comprise a blood system tumor, lymphoma, etc. Therefore, the tumor marker can be used for screening, molecular diagnosis, prognosis, and therapeutic effect evaluation for clinical multi-tumors (Pan-cancer).

The present application relates to a kind of small sample endometrial carcinoma target delineation method, belong to target delineation technical field, solve the problem of low segmentation accuracy caused by small sample data training model in prior art.The method comprises the following steps: constructing multiple data centers, each data center includes multiple-channel segmentation model and multiple modal endometrial carcinoma sample set;The pre-training of the multiple-channel segmentation model is carried out based on the multiple data centers, and the pre-trained endometrial carcinoma target segmentation model is obtained;The pre-trained endometrial carcinoma target segmentation model is fine-tuned on target data set, and the trained endometrial carcinoma target segmentation model is obtained;Based on the trained endometrial carcinoma target segmentation model, the multiple modal endometrial carcinoma image to be segmented is segmented, and the target delineation result of the multiple modal endometrial carcinoma image to be segmented is obtained.The high-efficiency and accurate endometrial carcinoma target delineation is realized.

The present application relates to the field of biotechnology, and more particularly to an inhibitory peptide targeting p53 protein and application thereof. The present application uses IDProMat to design and obtain the inhibitory peptide targeting p53 protein according to the core binding site of the binding interface of the p53 protein core domain and ASPP2, TSPYL5, iASPP and the like; the inhibitory peptide can bind to p53 protein, competitively block the interaction between E3 ubiquitin ligase COP1 and p53, inhibit the ubiquitination degradation of p53, restore the anticancer function of p53, and has good biological safety and metabolic stability, and is expected to be used for clinical treatment of ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer and the like.

The invention relates to a small sample endometrial cancer target region sketching method, belongs to the technical field of target region sketching, and solves the problem of low segmentation accuracy caused by a small sample data training model in the prior art. The method comprises the following steps: constructing a plurality of data centers, wherein each data center comprises a multi-channel segmentation model and a multi-modal endometrial cancer sample set; pre-training the multi-channel segmentation model based on the plurality of data centers to obtain a pre-trained endometrial cancer target region segmentation model; performing fine adjustment on the pre-trained endometrial cancer target region segmentation model on a target data set to obtain a trained endometrial cancer target region segmentation model; and segmenting a to-be-segmented multi-modal endometrial cancer image based on the trained endometrial cancer target region segmentation model to obtain a target region sketching result of the to-be-segmented multi-modal endometrial cancer image. The efficient and accurate delineation of the endometrial cancer target region is realized.

The present invention belongs to the technical field of cell line construction, and particularly relates to a STK11 flox / flox LTF Cre / ‑ Transgenic mouse endometrial tumor cell line and its application. flox / flox LTF Cre / ‑ The deposit number of the transgenic mouse endometrial tumor cell line is CCTCC NO: C2022278. The cell line provided by the present invention has good wall adhesion performance, stable cell characteristics, can be stably passaged for multiple times, has uniform morphological characteristics during passage, can maintain typical characteristics of epithelial cells during passage, has clinical biological characteristics close to tumors, has strong proliferation activity and tumor formation ability, has a high tumor formation rate, is suitable for establishing an endometrial tumor animal model, and provides new ideal experimental materials that are closer to clinical tumor biological characteristics for studying the occurrence and development molecular mechanism of endometrial cancer and screening anti-endometrial cancer drugs.

The invention discloses screening and application of an endometrial cancer plasma metabolism marker composition. Based on metabonomics research, a group of metabolic marker compositions with significant difference are screened out by analyzing and comparing metabolites in plasma of endometrial cancer patients and healthy people. By means of the screened markers, early, rapid and accurate detection of endometrial cancer can be achieved, so that treatment measures can be taken in time, and the survival rate and life quality of patients are improved. The metabolic marker obtained by the invention has the advantages of non-invasive detection, high sensitivity and specificity, high throughput analysis, cost effectiveness and early screening. Early discovery and treatment of diseases such as cancers are facilitated, and prognosis is improved. In practical application, excellent performance and huge potential are shown, and a new direction is provided for disease diagnosis and health management in the future.

The present technology provides compounds, as well as compositions including such compounds, useful for imaging and / or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and / or a prostate cancer.